Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

Cancer Research

Volumn 68, Issue 19, 2008, Pages 8049-8057

  Horton, Holly M ^a   Bernett, Matthew J ^a   Pong, Erik ^a   Peipp, Matthias ^b   Karki, Sher ^a   Chu, Seung Y ^a   Richards, John O ^a   Vostiar, Igor ^a   Joyce, Patrick F ^a   Repp, Roland ^b   Desjarlais, John R ^a   Zhukovsky, Eugene A ^a  

^a Xencor Inc   (United States)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIBODY; CD19 ANTIGEN; FC RECEPTOR; MONOCLONAL ANTIBODY X5574; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR BINDING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; LEUKEMIA; LYMPHOMA; MICE; MICE, KNOCKOUT; MICE, SCID; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, IGG; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54249100952     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2268     Document Type: Article

References (51)

1. Tedder TF, Inaoki M, Sato S. The CD19-21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997;6:107-18.
2. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33.
3. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998;51:364-9.
4. Harris NL, Stein H, Coupland SE, et al. New approaches to lymphoma diagnosis. Hematology Am Soc Hematol Educ Program 2001:194-220.
5. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-5.
6. Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002;119:412-6.
7. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: Rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007;2007:233-42.
8. Vlasveld LT, Hekman A, Vyth-Dreese FA, et al. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 1995;40:37-47.
9. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci US A 2005;102:15178-83.
10. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993;11:726-37.
11. Rowland AJ, Pietersz GA, McKenzie IF. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol Immunother 1993;37:195-202.
12. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4.
13. Molhoj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007;44:1935-43.
14. Bruenke J, Barbin K, Kunert S, et al. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgRIII (CD16). Br J Haematol 2005;130:218-28.
15. Hekman A, Honselaar A, Vuist WM, et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 1991;32:364-72.
16. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7.
17. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by antitumor antibodies: an engineer's perspective. Drug Discov Today 2007;12:898-910.
18. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54.
19. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci US A 2006;103:4005-10.
20. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J Biol Chem 2001;276:6591-604.
21. Stavenhagen JB, Gorlatov S, Tuaillon N, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcg receptors. Cancer Res 2007;67:8882-90.
22. Tedder TF, Baras A, Xiu Y. Fcg receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 2006;28:351-64.
23. Meeker TC, Miller RA, Link MP, Bindl J, Warnke R, Levy R. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma 1984;3:305-20.
24. Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 2007;44:1986-98.
25. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368:652-65.
26. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
27. Peipp M, Schneider-Merck T, Dechant M, et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 2008;180:4338-45.
28. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008;7:2517-27.
29. Chatenoud L, Bach JF. Antigenic modulation - a major mechanism of antibody action. Immunol Today 1984;5:20-5.
30. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12.
31. Ingle GS, Chan P, Elliott JM, et al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br J Haematol 2008;140:46-58.
32. Barbin K, Stieglmaier J, Saul D, et al. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies. J Immunother (1997) 2006;29:122-33.
33. Benoit NE, Wade WF. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin. Immunopharmacology 1996;35:129-39.
34. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992;149:2841-50.
35. Xu Y, Szalai AJ, Zhou T, et al. FcgRs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol 2003;171:562-8.
36. Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol 2006;33:S2-14.
37. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-36.
38. Nijmeijer B, van Schie MLJ, Willemze R, Falkenburg JHF. Rituximab and alemtuzumab in combination, but not alone, induce complete remissions in a preclinical animal model of primary human ALL: rationale for combination treatment [abstract]. Blood 2007;110:2833.
39. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia-long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma 2003;44:1719-25.
40. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
41. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002;99:754-8.
42. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
43. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
44. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005;310:1510-2.
45. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:474-81.
46. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcg receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006;203:743-53.
47. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69.
48. McEarchern JA, Oflazoglu E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007;109:1185-92.
49. Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der Schoot CE, von dem Borne AE, Slaper-Cortenbach IC. Fc g receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood 1994;83:1632-9.
50. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001;167:163-72.
51. Sieber T, Schoeler D, Ringel F, Pascu M, Schriever F. Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2003;121:458-61.